Shuji Sumitomo
Overview
Explore the profile of Shuji Sumitomo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
1056
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iwasaki T, Yoshifuji H, Kitagori K, Sumitomo S, Akizuki S, Nakashima R, et al.
Front Immunol
. 2025 Feb;
16:1506298.
PMID: 39975549
The factors contributing to the treatment efficacy of belimumab in patients with systemic lupus erythematosus (SLE) in the maintenance phase are unknown. Here, we collected blood samples from patients with...
2.
Kachi S, Oka H, Sumitomo S, Hara S, Ohmura K
Mod Rheumatol Case Rep
. 2024 Dec;
PMID: 39670676
IgG4-related disease (IgG4-RD) is a systemic, immune-mediated, fibroinflammatory disorder that affects multiple organs. Histopathologically, the supportive findings of IgG4-RD include dense lymphocytic infiltrates, obliterative phlebitis, storiform fibrosis, and elevated numbers...
3.
4.
Oka H, Sumitomo S, Shimizu H, Ohmura K
Clin Exp Rheumatol
. 2024 Sep;
42(10):2100-2101.
PMID: 39230746
No abstract available.
5.
Taguchi H, Sumitomo S, Oka H, Hara S, Ohmura K
Mod Rheumatol Case Rep
. 2024 Jul;
9(1):193-199.
PMID: 39082153
Löfgren syndrome (LS) is a sarcoidosis subtype characterised by an acute disease course, bilateral hilar lymphadenopathy (BHL), erythema nodosum (EN), and ankle arthritis. LS in Caucasians appears to be self-limiting;...
6.
Tsuchiya H, Ota M, Takahashi H, Hatano H, Ogawa M, Nakajima S, et al.
Inflamm Regen
. 2024 Jun;
44(1):29.
PMID: 38831367
Background: Current strategies that target cytokines (e.g., tumor necrosis factor (TNF)-α), or signaling molecules (e.g., Janus kinase (JAK)) have advanced the management for allergies and autoimmune diseases. Nevertheless, the molecular...
7.
Nakayama Y, Nagata W, Takeuchi Y, Fukui S, Fujita Y, Hosokawa Y, et al.
Mod Rheumatol
. 2024 May;
34(6):1079-1094.
PMID: 38814660
Objectives: The aim of this article is to update evidence on the efficacy and safety of disease-modifying antirheumatic drugs (DMARDs) and provide information to the taskforce for the 2024 update...
8.
Kachi S, Sumitomo S, Oka H, Hata A, Ohmura K
Front Immunol
. 2024 May;
15:1400097.
PMID: 38799449
This report describes the case of a 48-year-old woman who presented with sternoclavicular joint arthritis after administration of an immune checkpoint inhibitor (ICI), durvalumab, for small cell lung carcinoma. The...
9.
Oka H, Sumitomo S, Ohmura K
JAMA
. 2023 Dec;
330(24):2388-2389.
PMID: 38048123
No abstract available.
10.
Taguchi H, Shirota S, Sumitomo S, Hara S, Ohmura K, Nishioka H
Int J Rheum Dis
. 2023 Oct;
27(1):e14950.
PMID: 37875280
No abstract available.